Dr. Nazarian is Head of the Translational Program at DIPG/DMG Research Center [smex-ctp.trendmicro.com], University Children’s Hospital in Zürich, Switzerland [uzh.ch], the Scientific Director of the Brain Tumor Institute at Children’s National, and the Scientific Co-Chair of the Children’s Brain Tumor Network [cbtn.org] (CBTN). Tenured Associate Professor, Genomics and Precision Medicine, George Washington University School of Medicine and Health Sciences [smhs.gwu.edu]. As part of his effort to identify the molecular pathways driving childhood brain cancers, Dr. Nazarian established a comprehensive biorepository which is used to establish disease preclinical models and study tumor microenvironment. He has also worked with multiple institutions and collaborators to establish an international collaborative team focusing on the development of novel clinical designs to treat children diagnosed with DIPG/DMG known as the DMG-ACT (DMG-Adaptive and Combination Therapies) clinical trial which is operated through Pacific Pediatric Neuro-Oncology Consortium (PNOC). Under Dr. Nazarian’s leadership, this team has generated robust preliminary data that have supported initiation of two promising trials through PNOC using ONC206 (NCT04732065), and a highly innovative biology-informed DMG platform trial (NCT05009992), capable of adding in treatment arms based on new discoveries.
